|Left, Anneke van der Walt; right, Helmut Butzkueven|
at the annual "Kiss Goodbye to MS" awareness event
They found that therapies, effective for other forms of MS, have no substantial effect on short- to medium-term disability outcomes in PPMS.
Disability outcomes using the Expanded Disability Status Scale (EDSS) were compared between people who had treatment (194) and those without treatment (338), with the average follow-up time of 3.4 years. No statistically significant differences were found between the groups.
Current treatment options for people with primary progressive multiple sclerosis (MS) are limited. Further research studies are urgently needed for people with primary progressive MS to improve their health and wellbeing.
Reference: Lorscheider, Kuhle, Izquierdo…Van der Walt, Butzhueven, Kappos, Kalincik, MS Base Investigators. Anti-inflammatory disease modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study. Eur J Neurol. Ahead of print, 9 October 2018. https://doi.org/10.1111/ene.13824